Our Work

Firm Advises as RDIF, RCIF, and Middle Eastern Investors Acquire Stake in OBL Pharm

August 19, 2019

Transaction represents a milestone in the creation of a major Russian pharmaceuticals group.

Sistema PJSFC, a publicly traded diversified Russian holding company, has announced that a consortium of investors comprising the Russian Direct Investment Fund (RDIF), the Russia-China Investment Fund (RCIF) established by the RDIF and China Investment Corporation, and leading Middle Eastern funds (the Investment Consortium) have completed the acquisition of a minority stake in OBL Pharm for an amount exceeding RUB4 billion.

Latham & Watkins advised Sistema in the transaction with a Moscow team led by corporate partner Olga Ponomarenko with associates Timur Bayramov, Oksana Uberwolf, and Vladimir Mikhailovsky.

Endnotes

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.